Quralis Corporation
Cambridge, MA
- UEI
- ZHB4WDW8MB37
- CAGE
- 7YD39
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 35 Cambridgepark Dr Suite 300, Cambridge, MA 02140, USA
- Website
- quralis.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Acurastem Incorporated | Pasadena, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Formation Venture Engineering Foundry Inc. | Topsfield, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| A L S Therapy Development Institute | Watertown, MA | — |
| Microquin LTD | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Adrx, Inc. | Thousand Oaks, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Quralis Corp is a biotech company focused on developing precision medicine solutions to cure amyotrophic lateral sclerosis (ALS) and genetically linked frontotemporal dementia (FTD). Through federal grant awards, Quralis Corporation provides biomedical research and development services related to biomarkers and therapeutics for ALS and FTD.
Specifically, Quralis Corporation has received federal grant funding to support preclinical and clinical research on an STMN2-based biomarker to identify ALS patients and monitor treatment efficacy, as well as early-stage development of a therapeutic candidate that modulates STMN2 splicing. Additional federal grants have supported Quralis' development of cellular models and assays to enable drug discovery for ALS. These federal grants have been awarded by the Department of the Army Medical Command under the Military Medical Research and Development program, as well as the National Institutes of Health through the National Institute of Neurological Disorders and Stroke. The grants have included both direct federal funding and pass-through funding via subawards from research institutions. Through this federal grant funding, Quralis advances innovative scientific solutions for ALS, FTD, and related neurodegenerative diseases.
Quick answers
Is Quralis Corporation registered in SAM.gov?
Yes. Quralis Corporation's SAM.gov registration is active through September 9, 2027.
What is Quralis Corporation's most recent federal award?
Quralis Corporation's most recent federal grant award is Validation of a STMN2-based biomarker for ALS patient identification and target engagement in clinical studies (W81XWH2211098), from Defense Health Agency, on September 30, 2022.
On GovTribe
See Quralis Corporation's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors